Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of rs7903146 Genotype on Islet GLP-1 Production
NCT06972407Phase 2Not yet recruiting
- Sponsor
- Mayo Clinic
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of exendin 9-39 in type 2 diabetes mellitus (T2DM), sponsored by Mayo Clinic. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
exendin 9-39
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06972407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972407.